305 related articles for article (PubMed ID: 23943337)
1. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Rollini F; Tello-Montoliu A; Patel R; Darlington A; Wilson RE; Franchi F; Muñiz-Lozano A; Desai B; Bender N; Sakariassen KS; Angiolillo DJ
J Thromb Thrombolysis; 2014; 37(2):131-8. PubMed ID: 23943337
[TBL] [Abstract][Full Text] [Related]
2. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P
Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330
[TBL] [Abstract][Full Text] [Related]
3. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y
Platelets; 2013; 24(2):145-50. PubMed ID: 22385219
[TBL] [Abstract][Full Text] [Related]
5. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Angiolillo DJ; Jakubowski JA; Ferreiro JL; Tello-Montoliu A; Rollini F; Franchi F; Ueno M; Darlington A; Desai B; Moser BA; Sugidachi A; Guzman LA; Bass TA
J Am Coll Cardiol; 2014 Sep; 64(10):1005-14. PubMed ID: 25190236
[TBL] [Abstract][Full Text] [Related]
6. Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Duerschmied D; Ahrens I; Mauler M; Brandt C; Weidner S; Bode C; Moser M
PLoS One; 2012; 7(2):e32656. PubMed ID: 22384279
[TBL] [Abstract][Full Text] [Related]
7. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
Liang Y; Johnston M; Hirsh J; Pare G; Li C; Mehta S; Teo KK; Sloane D; Yi Q; Zhu J; Eikelboom JW
J Thromb Thrombolysis; 2012 Nov; 34(4):429-36. PubMed ID: 22797934
[TBL] [Abstract][Full Text] [Related]
8. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Rollini F; Franchi F; Cho JR; Degroat C; Bhatti M; Ferrante E; Patel R; Darlington A; Tello-Montoliu A; Desai B; Ferreiro J; Muniz-Lozano A; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
J Cardiovasc Transl Res; 2014 Feb; 7(1):53-63. PubMed ID: 24395495
[TBL] [Abstract][Full Text] [Related]
9. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study.
Velik-Salchner C; Maier S; Innerhofer P; Streif W; Klingler A; Kolbitsch C; Fries D
Anesth Analg; 2008 Dec; 107(6):1798-806. PubMed ID: 19020120
[TBL] [Abstract][Full Text] [Related]
10. Normalization of platelet reactivity in clopidogrel-treated subjects.
Vilahur G; Choi BG; Zafar MU; Viles-Gonzalez JF; Vorchheimer DA; Fuster V; Badimon JJ
J Thromb Haemost; 2007 Jan; 5(1):82-90. PubMed ID: 17239165
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
12. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
13. Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.
Tello-Montoliu A; Ferreiro JL; Kodali MK; Ueno M; Tomasello SD; Rollini F; Capodanno D; Darlington A; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
J Thromb Thrombolysis; 2013 Jul; 36(1):14-7. PubMed ID: 23143668
[TBL] [Abstract][Full Text] [Related]
14. Determination of aspirin responsiveness by use of whole blood platelet aggregometry.
Ivandic BT; Giannitsis E; Schlick P; Staritz P; Katus HA; Hohlfeld T
Clin Chem; 2007 Apr; 53(4):614-9. PubMed ID: 17332149
[TBL] [Abstract][Full Text] [Related]
15. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
16. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
[TBL] [Abstract][Full Text] [Related]
17. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
[TBL] [Abstract][Full Text] [Related]
18. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease.
Grove EL; Hvas AM; Mortensen SB; Larsen SB; Kristensen SD
J Thromb Haemost; 2011 Jan; 9(1):185-91. PubMed ID: 20955349
[TBL] [Abstract][Full Text] [Related]
19. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Diabetes; 2006 Mar; 55(3):780-4. PubMed ID: 16505243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
